EUVIMEDEUVIMED entdecken
Open Access

IFNL4 Genotype Frequencies in Asian Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured

Thomas R O'Brien iD, Mei-Hsuan Lee, Eleanor Wilson, Shyam Kottilil

Journal of Interferon & Cytokine Research · 2023

DOI: 10.1089/jir.2023.0022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Interferon & Cytokine Research, 2023. Verfasst von Thomas R O'Brien und 3 weiteren Autor:innen. Beteiligte Einrichtung: Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Globally, ∼56.8 million people are chronically infected with hepatitis C virus (HCV), with about half residing in Asia. The cost and efficiency of delivering regimens based on direct-acting antiviral agents for HCV are important considerations in implementing these curative treatments. For sofosbuvir-based regimens, most patients are treated for 12 weeks; however, treatment for 8 weeks has been shown to cure HCV infection in 95% of patients without cirrhosis. Furthermore, virological failure after 8-week treatment occurs in only 1%–2% of individuals without cirrhosis, who have a favorable IFNL4 genotype, which is present in >50% of South Asians and >80% of East Asians. We propose that sofosbuvir-based treatment for 8 weeks, or perhaps shorter, would yield high response rate regimens in Asian countries and markedly increase the number of patients who could be cured for a given cost of the medication. We propose that a noninferiority trial in an East Asian population be conducted to test this hypothesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicHepatitis CHumansSofosbuvirAntiviral AgentsHepacivirusRibavirinDrug Therapy, CombinationLiver CirrhosisGenotypeTreatment OutcomeInterleukinsInterferon Lambda

Stichwörter der Autor:innen

IFNL4cost-effectivenesspublic healthtreatment response

Substanzen

SofosbuvirAntiviral AgentsRibavirinInterleukinsIFNL4 protein, humanInterferon Lambda

Autor:innen und Institutionen

  • Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
  • Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Thomas R O'Brien

Zitieren

APA

O'Brien, T. R., Lee, M. H., Wilson, E., & Kottilil, S. (2023). IFNL4 Genotype Frequencies in Asian Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured. Journal of Interferon & Cytokine Research. https://doi.org/10.1089/jir.2023.0022

Vancouver

O'Brien TR, Lee MH, Wilson E, Kottilil S. IFNL4 Genotype Frequencies in Asian Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured. Journal of Interferon & Cytokine Research. 2023. doi:10.1089/jir.2023.0022

BibTeX
@article{OBrien2023,
  author = {O'Brien, Thomas R and Lee, Mei-Hsuan and Wilson, Eleanor and Kottilil, Shyam},
  title = {IFNL4 Genotype Frequencies in Asian Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured},
  journal = {Journal of Interferon & Cytokine Research},
  year = {2023},
  doi = {10.1089/jir.2023.0022}
}
Kostenlos starten →